Now, we’re using these capabilities to develop purpose-built #miniprotein medicines designed to match the complexity of human disease.

This is the foundation for our next chapter at @aiproteins.com. We’ve industrialized the process of creating #miniproteins de novo while fully controlling every aspect of their activity and properties.

In this talk, I explain how our #miniproteins can interact with as many targets as needed to deliver the exact therapeutic outcome that patients require. This level of sophistication is unprecedented and will impact indications across oncology, inflammation, and beyond.

To truly control biology, we need medicines that can engage multiple targets simultaneously, but traditional modalities like small molecules and antibodies struggle to do this.

Biology is dizzyingly complex, and yet almost every medicine humanity has ever made acts on a single target in the body. Just a handful can interact with two distinct targets, and these are some of the most exciting treatments to enter the clinic in the past decade.

It’s a privilege to be building @aiproteins.com together with James and our unbelievably talented and dedicated team of people, all striving to make a difference in the world through our technology

www.businesswire.com/news/home/20...

As our first CTO at @aiproteins.com, James will lead the continued acceleration of our platform capabilities in addition to the design, testing and optimization of many novel #miniprotein drug candidates

Our mission is to industrialize drug discovery to create programmable, #denovo protein-based medicines that help patients across a wide range of diseases

James has been one of the key architects of this vision since day one, and his insight and leadership these past ~4 years has shaped the discovery engine that powers @aiproteins.com today

What began as an idea — that we could scale de novo protein design — is now a fully-operational platform that integrates generative #AI with automated production and characterization in the wet lab

James joined my academic lab at the @ipiproteins.bsky.social in January of 2020 as a postdoc focused on #miniprotein de novo design and engineering. Less than 2 years later, James and I left academia together to found @aiproteins.com along with an incredible team of people from my former lab.

And most importantly, a huge thank you to the phenomenal team at @aiproteins.bsky.social

Your dedication, ingenuity, and relentless pursuit of innovation are the driving force behind the amazing work we do. It's a privilege to lead such a talented group and to share our achievements with the world

I'm so grateful to Lily James Olds, Leonie Hoerster and Allegra Pearl from TED Conferences for providing such incredible support

This is why I'm so excited to have Phil as our newest colleague - he's the best person on the planet to help us pave the way, and I know that we're going to create many amazing molecules together that improve the lives of patients everywhere.

Our de novo miniproteins are a novel modality, which means that we're writing the playbook for #miniprotein drug development as we go.